Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.54 |
| ▸ | CDK2 | P24941 | 7/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12954304 | 0.94 | GSK3B (0.55) | GSK3BCDK2CCNA2CCNA1ADORA2A | |
| SCHEMBL14043292 | 0.90 | GSK3B (0.57) | GSK3BCDK2CCNA2CCNA1ADORA2A | |
| SCHEMBL14043294 | 0.89 | GSK3B (0.49) | GSK3BCDK2CCNA2CCNA1ADORA2A | |
| SCHEMBL12953680 | 0.88 | GSK3B (0.71) | GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL13305019 | 0.88 | GSK3B (0.54) | GSK3BCDK2CCNA2CCNA1ADORA2A | |
| SCHEMBL13304787 | 0.87 | GSK3B (0.47) | GSK3BCDK2CCNA2CCNA1ADORA2A | |
| SCHEMBL13305327 | 0.84 | GSK3B (0.45) | GSK3BCDK2CCNA2CCNA1POLB | |
| SCHEMBL13305701 | 0.84 | GSK3B (0.45) | GSK3BCDK2CCNA2CCNA1ADORA2A | |
| SCHEMBL12953478 | 0.83 | GSK3B (0.70) | GSK3BCDK2CCNA2CCNA1 | |
| SCHEMBL12953665 | 0.82 | GSK3B (0.63) | GSK3BCDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |